Genmab A/S (NASDAQ:GMAB) Receives $45.20 Average Target Price from Analysts

Shares of Genmab A/S (NASDAQ:GMAB - Get Free Report) have received an average recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $45.20.

Several research analysts have issued reports on GMAB shares. Morgan Stanley reiterated an "equal weight" rating and set a $31.00 price objective on shares of Genmab A/S in a research note on Wednesday, September 11th. Truist Financial cut their price target on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a report on Monday, September 9th. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Genmab A/S in a report on Tuesday, August 20th. BMO Capital Markets restated an "outperform" rating and set a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a report on Wednesday, October 16th.

Genmab A/S Price Performance

Shares of Genmab A/S stock traded up $0.14 during trading on Monday, hitting $20.79. 2,744,784 shares of the company's stock traded hands, compared to its average volume of 723,006. The company has a market cap of $13.76 billion, a PE ratio of 20.05, a PEG ratio of 0.64 and a beta of 0.99. The firm's fifty day moving average price is $23.16 and its 200 day moving average price is $25.86. Genmab A/S has a twelve month low of $20.34 and a twelve month high of $32.88.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The company had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. During the same period in the previous year, the firm posted $0.47 earnings per share. As a group, equities research analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently modified their holdings of the business. Oppenheimer Asset Management Inc. increased its holdings in Genmab A/S by 26.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company's stock valued at $5,480,000 after purchasing an additional 45,376 shares during the last quarter. Choreo LLC bought a new stake in shares of Genmab A/S in the 2nd quarter valued at about $776,000. Renaissance Technologies LLC raised its position in shares of Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock valued at $36,752,000 after acquiring an additional 103,859 shares during the period. US Bancorp DE raised its position in shares of Genmab A/S by 16.0% in the 3rd quarter. US Bancorp DE now owns 171,669 shares of the company's stock valued at $4,185,000 after acquiring an additional 23,723 shares during the period. Finally, Creative Planning boosted its stake in Genmab A/S by 136.3% during the 3rd quarter. Creative Planning now owns 47,422 shares of the company's stock worth $1,156,000 after acquiring an additional 27,353 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.